Start the conversation
I recently got the kind of news that no child wants to hear about an aging parent.
Here's the thing: I count my blessings that my dad lived so long. After all, he's a retired Marine Corps captain who saw three tours of combat, one in Korea and two in Vietnam.
Honestly, he's lucky he lived as long as he did. But that still doesn't make the aging process any easier, at least not on the body.
He recently had a second knee replacement that didn't go as well as planned. He also has swelling of the feet. His mobility is not all that great, and he can't drive right now.
At 86, he recently learned he has congestive heart failure. That's a condition in which the heart doesn't pump as strongly as it should, leading to a buildup of fluids.
As such, my dad is part of a huge trend in America. Fact is, according to the American Heart Association, cardiovascular disease is set to have an economic impact of $1.1 trillion by 2035.
And today, I want to reveal a life sciences firm that is bringing badly needed relief to millions of heart patients – and show you five reasons why it's set to double in as little as three-and-a-half years…
A Legacy of Expertise
To say that my dad and I are close is an understatement. He's the one who got me interested in high tech and defense in the first place.
After leaving the Marine Corps, he became the senior military editor for Aviation Week & Space Technology. For a time, he had a military technology newsletter, and I was his Silicon Valley bureau chief.
We don't talk as much as we used to, but for many years, we got on the phone once a week or so to chat about tech and issues of the day.
I recently visited him in his home in suburban Virginia, and I was pleased to see him in great spirits. He seems pretty nonplussed by it all.
On November 21st, we'll be unveiling a transformational breakthrough and a $2 million "surprise." You have to see this with your own eyes to believe it. But you must RSVP now.
Beyond medication, there's not much doctors can do at present to treat his heart. The good news is he could manage the condition and live several more years.
But for millions of folks with heart disease, more significant medical intervention is often required. Indeed, heart disease remains the leading cause of death in the United States, claiming more than 650,000 lives a year.
The impact here is staggering. The American Heart Association expects the cost of cardiovascular disease to rise to $1.1 trillion by 2035.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.